Quick Answer
Lexeo Therapeutics, Inc. reported Operating Income of -$109.26 million for fiscal year 2025.
Lexeo Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$109.26M | -3.3% |
| 2024 | -$105.77M | -54.4% |
| 2023 | -$68.51M | -13.2% |
| 2022 | -$60.51M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$21.65M | +31.4% | +29.5% |
| June 30, 2025 | -$30.69M | -30.3% | +9.2% |
| March 31, 2025 | -$33.80M | -45.1% | -7.2% |
| September 30, 2024 | -$31.54M | -55.6% | -33.9% |
| June 30, 2024 | -$23.55M | -68.5% | -1.1% |
| March 31, 2024 | -$23.29M | -20.7% | -14.9% |
| September 30, 2023 | -$20.27M | -16.0% | -45.1% |
| June 30, 2023 | -$13.97M | — | +27.6% |
- Lexeo Therapeutics, Inc. showed a decrease of -3.3% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, Lexeo Therapeutics, Inc.’s operating income has declined by 80.6% (from -$60.51 million to -$109.26 million).
- The most recent figure is from Lexeo Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: